Outset Tablo Could Boost Use of Home Hemodialysis
In data from a survey of 202 dialysis patients presented at the NKF Spring Clinicals meeting in Boston, MA, 77% said the features of the Tablo would make them more likely to try home HD. In addition, 77% of 184 nephrologist agreed that the Tablo features were “a significant improvement”—and 98% said they would be more likely to recommend home HD to their patients.
Read the full article » | Posted 05-12-2022
- FMC-NA is Company of Choice to Treat Veterans Posted 09-13-2022
- Outset Gets FDA Green Light Posted 08-11-2022
- Outset Halts Tablo Sales for Home Use Pending FDA Review of New Features Posted 07-13-2022
- Baxter Showcases Kidney Care Products Posted 06-10-2022